A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab or Tremelimumab Alone in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab or Tremelimumab Alone in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 14 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
    • 14 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 08 Dec 2016 Planned number of patients changed from 70 to 69.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top